[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585898":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":136,"collaborators":20,"id":138,"slug":139,"hasResults":140,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":20,"eligibilityCriteria":144,"healthyVolunteers":140,"sex":145,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":20,"studyType":151,"phases":152,"briefSummary":143,"conditions":154,"keywords":157,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"Praxis Precision Medicines","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Open-label 30mg\u002Fday PRAX-628 for 8 weeks","EXPERIMENTAL","Participants who meet all eligibility criteria will receive 30mg of PRAX-628 for 8 weeks.",[13],"Drug: 30mg PRAX-628",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","30mg PRAX-628","Once daily oral",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Medical Director","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Head of Pharmacovigilance","CONTACT","617-300-8460","clinicaltrials@praxismedicines.com",[32,46,55,64,73,82,91,100,108,118,126],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":20},"Praxis Research Site","RECRUITING","Phoenix","Arizona","85032","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-112.07404,33.44838,{"lat":44,"lon":43},{"facility":33,"status":34,"city":47,"state":48,"zip":49,"country":38,"countryCode":39,"cosmosGeoPoint":50,"geoPoint":54,"contacts":20},"Miami Lakes","Florida","30116",{"type":41,"coordinates":51},[52,53],-80.30866,25.90871,{"lat":53,"lon":52},{"facility":33,"status":34,"city":56,"state":57,"zip":58,"country":38,"countryCode":39,"cosmosGeoPoint":59,"geoPoint":63,"contacts":20},"Bethesda","Maryland","20817",{"type":41,"coordinates":60},[61,62],-77.10026,38.98067,{"lat":62,"lon":61},{"facility":33,"status":34,"city":65,"state":66,"zip":67,"country":38,"countryCode":39,"cosmosGeoPoint":68,"geoPoint":72,"contacts":20},"Chesterfield","Missouri","63005",{"type":41,"coordinates":69},[70,71],-90.57707,38.66311,{"lat":71,"lon":70},{"facility":33,"status":34,"city":74,"state":75,"zip":76,"country":38,"countryCode":39,"cosmosGeoPoint":77,"geoPoint":81,"contacts":20},"Hackensack","New Jersey","07601",{"type":41,"coordinates":78},[79,80],-74.04347,40.88593,{"lat":80,"lon":79},{"facility":33,"status":34,"city":83,"state":84,"zip":85,"country":38,"countryCode":39,"cosmosGeoPoint":86,"geoPoint":90,"contacts":20},"Middletown","New York","10941",{"type":41,"coordinates":87},[88,89],-74.42293,41.44593,{"lat":89,"lon":88},{"facility":33,"status":34,"city":92,"state":93,"zip":94,"country":38,"countryCode":39,"cosmosGeoPoint":95,"geoPoint":99,"contacts":20},"Round Rock","Texas","78681",{"type":41,"coordinates":96},[97,98],-97.6789,30.50826,{"lat":98,"lon":97},{"facility":33,"status":34,"city":101,"state":93,"zip":102,"country":38,"countryCode":39,"cosmosGeoPoint":103,"geoPoint":107,"contacts":20},"Seabrook","77586",{"type":41,"coordinates":104},[105,106],-95.02548,29.56412,{"lat":106,"lon":105},{"facility":33,"status":34,"city":109,"state":20,"zip":110,"country":111,"countryCode":112,"cosmosGeoPoint":113,"geoPoint":117,"contacts":20},"Heidelberg","03084","Australia","AU",{"type":41,"coordinates":114},[115,116],145.06667,-37.75,{"lat":116,"lon":115},{"facility":33,"status":34,"city":119,"state":20,"zip":120,"country":111,"countryCode":112,"cosmosGeoPoint":121,"geoPoint":125,"contacts":20},"Melbourne","03004",{"type":41,"coordinates":122},[123,124],144.96332,-37.814,{"lat":124,"lon":123},{"facility":33,"status":34,"city":127,"state":20,"zip":128,"country":129,"countryCode":130,"cosmosGeoPoint":131,"geoPoint":135,"contacts":20},"Madrid","28010","Spain","ES",{"type":41,"coordinates":132},[133,134],-3.70256,40.4165,{"lat":134,"lon":133},{"type":137,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100585898","phase-2-an-open-label-trial-to-evaluate-the-efficacy-and-safety-of-prax-628-in-adults-with-focal-onset-or-tonic-clonic-seizures-100585898",false,"NCT06908356","An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures","An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures","Inclusion Criteria:\n\n* A diagnosis of focal onset seizures or idiopathic generalized tonic clonic seizures.\n* Evidence by computed tomography (CT) or magnetic resonance imaging (MRI) in the past that has ruled out a progressive cause of epilepsy.\n* Participant must have been receiving stable doses of allowable ASMs (a minimum of 1 and a maximum of 3 ASMs).\n* Participant and\u002For caregiver (if applicable) self-reports at least 2 countable focal onset seizures per month for focal onset patients, or 1 countable generalized tonic-clonic seizure per month in the 3 months immediately prior to the Screening\u002FObservation Period for PGTCS patients.\n\nExclusion Criteria:\n\n* History of pseudo or psychogenic seizures, or cluster seizures only, within the 12-month period preceding study entry where the individual seizures cannot be counted, or an episode of convulsive status epilepticus requiring hospitalization and intubation in the 12 months prior to Screening.\n* Planned epilepsy surgery during the course of the clinical trial.\n* History of neurosurgery for seizures \\\u003C1 year prior to enrollment, or radiosurgery \\\u003C2 years prior to enrollment.\n* Schizophrenia and obsessive-compulsive disorder, or other serious mental health disorders.\n* Active suicidal plan\u002Fintent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt.\n* Participants with a history of malignancy, myeloproliferative or lymphoproliferative disorders within the past 5 years are excluded.\n* History of cardiac disease(s)\u002Fcardiac conduction disorders\u002For cardiac structural abnormality(ies).\n* Is pregnant or breastfeeding at the time of Screening, or has a positive serum pregnancy test at Screening or is planning to become pregnant during the clinical trial or within 14 days of the last study drug dose.\n* Has received any other experimental or investigational drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, or any prior use of gene therapy.\n* Vigabatrin: Use in the last 5 years without stable visual fields tested twice over the 12 months after the last dose of vigabatrin.\n* Felbamate: If used as a concomitant ASM, patients must be on felbamate for at least 2 years, with a stable dose for 2 months prior to Screening. If a patient received felbamate in the past, it must have been discontinued 2 months prior to Screening.","ALL","18 Years","75 Years",{"count":149,"type":150},50,"ESTIMATED","INTERVENTIONAL",[153],"PHASE2",[155,156],"Focal Onset Seizure","Primary Generalized Epilepsy",[155,156,158],"Tonic-Clonic","2025-03-26",{"date":161,"type":162},"2025-04-03","ACTUAL",{"date":164,"type":162},"2025-01-10",{"date":166,"type":150},"2025-07",{"name":5,"class":6},11]